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Abstract
Prostate cancer (PCa) remains a leading cause of cancer-related death in the USA. While localized 
lesions are effectively treated through radical prostatectomy and/or radiation therapy, treatment for 
metastatic disease leverages the addiction of these tumors on the androgen receptor (AR) signaling 
axis for growth and disease progression. Though initially effective, tumors resistant to AR-
directed therapeutics ultimately arise (a stage of the disease known as castration-resistant prostate 
cancer) and are responsible for PCa-specific mortality. Importantly, an abundance of clinical and 
preclinical evidence strongly implicates AR signaling cascades in the development of metastatic 
disease in both early and late stages, and thus a concerted effort has been made to delineate the 
AR-specific programs that facilitate progression to metastatic PCa. A multitude of downstream 
AR targets as well as critical AR cofactors have been identified which impinge upon both the AR 
pathway as well as associated metastatic phenotypes. This review will highlight the functional 
significance of these pathways to disseminated disease and define the molecular underpinnings 
behind these unique, AR-driven, metastatic signatures.
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1 Overview: prostate cancer development, treatment, and progression
Prostate cancer (PCa) is a leading health concern in the USA with nearly 32,000 deaths 
attributed to the disease annually [1]. It remains the most common noncutaneous malignancy 
diagnosed in US men and is the second leading cause of cancer-related deaths [1]. A 
favorable prognosis is heavy reliant upon early detection of the primary tumor, where 
localized lesions are effectively treated by radical prostatectomy and/or radiation therapy 
[2]. Disseminated disease, however, proves much more of a clinical challenge. Upon 
radiographic evidence of metastatic lesions (most commonly found in local lymph nodes 
and bone at the earliest stages), patients undergo systemic therapy to thwart cancer growth 
and progression [3–6]. Unlike other solid tumors, prostatic adenocarcinoma, both at primary 
and metastatic sites, responds poorly to standard chemotherapeutic intervention [7–9]. 
Therefore, first-line treatment for this disseminated disease leverages the addiction of these 
tumors on androgens for both growth and survival [4, 10, 11].
Molecular modeling of PCa has demonstrated that the action of androgens is manifest 
through activation of the androgen receptor (AR), whose activity is critical for PCa 
development and progression at all stages of disease [4]. As such, patients with metastatic 
tumors are treated with androgen deprivation therapy to biochemically dampen AR signaling 
[5, 6]. Initially, this therapy is quite effective resulting in either stable disease or tumor 
regression as measured biochemically (via serum prostate-specific antigen (PSA)) or 
radiographically [6, 11]. However, within 2 to 3 years, progression is often noted despite 
suppression of testosterone, a stage of the disease known as castration-resistant prostate 
cancer (CRPC). Herein, the AR signaling axis has been inappropriately reactivated allowing 
for upregulation of growth and survival pathways necessary for tumor proliferation and 
metastatic progression [10, 12, 13]. This results in enhanced metastatic tumor burden, and 
ultimately patient mortality [14]. As a result, there is an intense effort to not only more 
effectively target AR in CRPC, but to define the molecular pathways governed by AR which 
are responsible for such lethal metastatic events.
2 Role of AR in disease progression
AR is a large ~110 kDa transcription factor which belongs to the steroid nuclear receptor 
family, which functions as a ligand-dependent transcription factor necessary for 
development and function of the prostate [15]. In the normal prostate, AR plays a critical 
role in the early formation of the prostatic epithelia, directing key developmental programs 
responsible for proper formation of epithelial architecture and differentiation [15]. 
Importantly in this context, AR also acts to limit prostatic epithelial growth, which is 
essential for the development and function of prostatic tissue.
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As a function of tumorigenesis, the transcriptional targets of AR are altered, engaging pro-
proliferative programs essential for growth of prostatic adenocarcinoma cells [16]. 
Activation of this pathway is heavily reliant upon circulating androgens, which enter 
epithelial cells and are rapidly converted to the potent AR ligand 5α-dihydrotestosterone 
(5α-DHT) by the enzyme 5α-reductase [17]. This facilitates the binding of 5α-DHT to the 
ligand binding domain (LBD) of AR, shifting the position of helix 12 of the LBD towards 
the N-terminus [18, 19]. Functionally, this results in enhanced stability of the protein and 
release from inhibitory heat shock proteins. Agonist-bound AR translocates to the nucleus 
where it dimerizes and binds to chromatin in a site- and cell type-specific manner [20]. Once 
bound, AR undergoes a multitude of posttranslational modifications (including 
phosphorylation, methylation, sumoylation, and acetylation) [21, 22] which facilitate co-
factor recruitment and chromatin remodeling [23]. Ultimately, this leads to AR-specific 
programs critical for the survival and growth of PCa cells [16]. Clinically, the activity of AR 
can be monitored through the induction of the well-characterized AR target gene KLK3, 
which encodes a secreted protease PSA [6]. Levels of PSA can be monitored in patients 
serum and used a surrogate for AR activity and associated tumor burden [6]. As such, 
elevated or sustained increases in PSA levels are used (at least in part) as a marker of PCa 
development and progression.
2.1 Targeting AR in advanced disease
Work initiated by Huggins and Hodge in the early part of the twentieth century identified the 
first effective treatment for PCa, androgen deprivation therapy (ADT) [24–26]. To date, 
ADT still remains the most effective form of treatment for patients with disseminated 
disease. Standard of care options most often involve chemical castration through use of 
gonadotropin-releasing hormone (GnRH) agonists which, after an initial surge of 
testosterone production [27], suppress the secretion of leutinizing hormone (LH) and 
functionally inhibit testicular androgen synthesis [11, 28]. To prevent tumor growth in 
response to the testosterone flare, AR antagonists (e.g., biculatamide) are often given in 
combination with GnRH agonists, a therapeutic strategy known as total or maximum 
androgen blockade [11]. As a result, circulating testosterone levels often drop to levels seen 
in castrated males (<0.2 ng/dl [29]), which frequently correlate with a decline in serum PSA 
levels and stable or decreased tumor burden. Despite this, recurrence is common and within 
2–3 years patients begin to experience a resurgence of tumor growth heralded by increases 
in serum PSA levels (biochemical recurrence), indicative of a reengagement of the AR 
signaling axis.
At this stage of the disease (metastatic CRPC), tumors have evolved mechanisms to 
reactivate AR despite continued ADT. As reviewed [4, 10, 30], a multitude of pathways 
have been described which contribute to inappropriate AR activity in CRPC, many of which 
involve manipulation of AR itself (amplification, alternative splicing, mutation, and post-
translational modifications). Upstream of AR, however, recent evidence also suggests that 
tumors gain the ability to produce their own androgens, increasing the local androgen pool 
to sufficient levels to activate the AR axis [10, 31]. Microarray profiling of patient samples 
confirmed that key genes involved in the conversion of cholesterol derivatives to androgen 
precursors (CYP17A and HSDD3B2) are induced in response to ADT [32]. Consequently, 
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direct inhibitors of CYP17 have been developed (orteronel (TAK-700) [13], galeterone 
(TOK-001) [14]) and currently, abiraterone acetate is approved for the treatment of 
metastatic CRPC patients who have disease progression despite ADT both pre- and 
postchemotherapy [33–37]. In clinical trials, administration of abiraterone acetate 
significantly increased time to biochemical progression and radiographic progression-free 
survival, indicating that metastatic tumors are still reliant on AR signaling at this stage [34, 
35, 38]. As such, some clinical benefit has been seen with the introduction of novel anti-
androgens (e.g., Enzalutamide), which extended patient survival by ~3 months [39, 40]. 
However, once resistant to hormone-directed therapies, taxanes are the next therapeutic 
option for patients, which, unfortunately only affords a 2–3 months survival advantage (with 
a high rate of patient morbidity) [8, 9, 41]. As a result, there is a critical need to better define 
AR-driven networks responsible for lethal tumor phenotypes to more accurately and 
effectively combat metastatic disease.
2.2 Current strategies for targeting metastatic CRPC
Therapeutic options for treating disease that progresses after hormone therapy are extremely 
limited (Fig. 1). Taxane-based chemotherapy has proven to be the most effective 
chemotherapeutic in the management of metastatic CRPC [9, 41]. Preclinical evidence 
suggests that taxanes inhibit tubulin polymerization, a critical cytoskeletal protein involved 
in maintenance of cellular integrity and architecture, mitosis, intracellular transport, cell 
signaling, and gene expression. Docetaxel, a semisynthetic taxane derived from the needles 
of Taxus baccata that reversibly binds to microtubules with high affinity, has been 
demonstrated to provide a 20–24 % improvement in survival for men with metastatic 
castrate-resistant prostate cancer [9, 41] and was the first Food and Drug Administration-
approved agent for this patient population. Subsequent trials combining various 
chemotherapeutic or biologic agents to docetaxel have not yielded improved survival. 
However, preclinical work demonstrated that a second-line taxane, cabazitaxel, had 
cytotoxicity in cell lines and animal models both sensitive and resistant to docetaxel [36, 41, 
42]. While the mechanism of overcoming docetaxel resistance is unclear, clinical evidence 
has validated the efficacy of this agent as it was shown to improve survival in CRPC 
patients who had received prior docetaxel [43]. Given the effectiveness in the docetaxel-
pretreated patient population, there is currently an ongoing international randomized trial 
comparing first-line docetaxel versus cabazitaxel (trial #NCT01308567).
In addition to chemotherapy, a new agent was recently approved to treat CRPC of the bone. 
PCa primarily metastasizes to bone, where tumor growth leads to high fracture rates and is 
associated with patient morbidity [44, 45]. Clinically, high tumor burden at such metastatic 
sites correlates with decreased survival time [14], yet few therapeutic options are available 
which specifically target tumors at these sites. Currently, only Radium-223 dichloride (a 
radioactive α-emitting isotope which mimics the valence structure of calcium ions) has been 
developed as an effective treatment strategy for bone-specific metastases [36, 46]. A phase 
III clinical trial of CRPC patients demonstrated that treatment with Radium-223 
significantly reduced first skeletal-related events and prolonged overall survival (~3 months) 
as compared to placebo [46]. Interestingly, however, it is unknown as to how effective 
Radium-223 would be in the hormone therapy (HT)-naive setting. Clinical data suggests that 
Augello et al. Page 4
Cancer Metastasis Rev. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
an intact AR signaling axis is critical for the progression of metastatic lesions. Thus it is 
tempting to speculate that combination ADT and Radium-223 would effectively inhibit PCa 
progression in hormone-sensitive metastatic disease. Future efforts will likely test this 
hypothesis to determine if such combinations could be leveraged for patient benefit. While 
Radium-223 represents a significant step forward in combating metastatic PCa progression, 
few strategies have been developed which specifically target metastatic programs unique to 
PCa.
3 Role of the AR in the development of metastatic disease
Given the poor prognosis associated with the development of metastatic prostate cancer and 
the known role of AR in promoting disease progression, a concerted effort was undertaken 
to identify the functions(s) by which AR facilitates the metastatic process and/or 
maintenance of metastatic disease. As will be reviewed herein, translational investigative 
studies revealed major roles for AR in promoting prometastatic events, through: (1) 
differential chemokine receptor/ligand function; (2) altered function of tumor-associated AR 
cofactors (e.g., FOXA1, cyclin D1b, and SWI/SNF); and (3) formation of prometastatic, 
AR-dependent gene fusions and downstream effectors (e.g., SOX9).
3.1 I. Chemokine and chemokine receptor dysregulation in PCa
Chemokine receptors belong to the G-protein coupled receptor (GPCR) family of proteins. 
There are over 20 known members of this family each of which contains a generally 
conserved structure consisting of a seven-pass transmembrane monomer and a soluble 
cytoplasmic tail [47, 48]. While expression is fairly ubiquitous, these receptors are known to 
have significant roles in the immune response, development, angiogenesis, and 
inflammation. Activation occurs upon ligand binding (chemokine family of soluble ligands) 
which initiates a series of signal transduction pathways responsible for mediating a 
multitude of cellular responses including actin skeleton rearrangements, calcium signaling, 
and survival (among others). Given the critical role these pathways play in cancer 
progression, chemokine receptors are often deregulated in human disease [47–49]. 
Importantly, as several of these receptors (and their ligands) have been shown to be 
regulated by AR [50, 51], there is growing interest in determining the relevance of these 
receptors in mediating metastatic phenotypes in both hormone therapy-sensitive and 
castration-resistant prostate cancer.
3.1.1 CXCR4—CXCR4 is a 352 amino acid GPCR which is activated though association 
with its soluble ligand SDF1 (also known as CXCL12) [47]. Upon activation, intramolecular 
signaling cascades (which vary with cell type) are transmitted through the cell, culminating 
in cytoskeletal rearrangements which promote migration towards the site of activation as 
well as transcriptional programs which regulate growth and survival [47]. The prostate gland 
is one of the few soft tissues which express detectable levels of CXCR4, though it is unclear 
if it plays a significant role in normal prostatic function [52]. Importantly, however, as a 
function of tumorigenesis, there is a marked induction of CXCR4 both at the transcript and 
protein levels [53]. Immunohistochemical analyses of PCa lesions confirm heightened 
expression of the receptor in both primary and metastatic disease (compared to benign 
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control), with the highest expression detectable in bone metastases [53]. Of note, tissue-wide 
interrogation of SDF-1 expression indicated that bone expresses relatively high levels SDF-1 
[54]; the bone representing a preferential site for PCa metastatic colonization. This supports 
the concept that induction of CXCR4 (as a consequence of tumorigenesis) functions to 
promote metastatic progression via attraction to the high SDF-1 gradient generated in tissues 
such as bone. While more clinical data is needed to confirm such conclusions, multiple 
clinically relevant models have demonstrated that CXCR4 is regulated as a function of 
androgen signaling, and it is likely that the interplay between the two promotes lethal 
metastatic events.
Multiple AR-positive PCa models have been used to describe enhanced migratory potential 
of CXCR4 expressing cells towards a gradient generated by SDF-1 [50]. Importantly 
however, such phenotypes were only observable in the presence of androgen, indicating that 
CXCR4-dependent metastatic phenotypes required an intact AR signaling axis [50]. Such 
conclusions are supported by transcriptional evidence which demonstrates robust induction 
of CXCR4 transcript in response to androgen stimulation [50], which can be reversed 
though either administration of ADT or direct AR antagonists. Exploration into the 
underlying mechanisms behind AR-induced CXCR4 expression revealed that the 
relationship was likely indirect. Chip sequencing analyses from multiple AR-positive cell 
lines lacked AR binding within a 50 kb window of the transcriptional start site [55, 56]. 
Such conclusions were confirmed wherein ligand bound AR was unable to promote CXCR4 
induction in the presence of protein synthesis inhibitors. Subsequent analysis of AR-
regulated transcription factors capable of fostering CXCR4 expression uncovered Kruppel-
like-factor 5 (KLF5) as a potential candidate [50]. Indeed, transcript analyses from LNCaP 
cells revealed a robust and rapid induction of KLF5 transcript upon AR activation. 
Additionally, expression of exogenous KLF5 in a low-androgen setting was sufficient to 
promote CXCR4 expression and invasion toward an SDF-1 generated gradient [50]. 
Collectively, these data demonstrate a tumor-specific AR-driven pathway which promotes 
invasive phenotypes in vitro. While intriguing, it will be critical to determine if AR/KLF5-
induced CXCR4 expression is sufficient to promote metastatic phenotypes in vivo, and 
whether or not such pathways are preserved in CRPC tumors. In addition, profiling of the 
ERG cistrome and transcriptome identified CXCR4 as a putative target of ERG signaling in 
fusion-positive disease [57]. Given the known metastatic functions of ERG, AR, and 
CXCR4, it will be important to determine how the interplay between these factors cooperate 
to promote metastatic disease, and if this pathway offers a novel therapeutic target to thwart 
metastatic progression in AR-positive, fusion-positive disease.
3.1.2 CX3CR1/fractalkine—While there is an abundance of literature examining tumor-
associated androgen signaling and its role in mediating metastatic programs, there is a gap in 
knowledge as to the potential role of AR in facilitating metastatic events in distal tissues. 
Though AR is expressed in many tissues, its activity greatly influences bone development 
[58]. Congruent with this concept, a recent study has identified a novel role for androgen 
signaling in regulating the cleavage of fractalkine (CX3CL1), a membrane-bound cytokine 
which is expressed human bone marrow endothelial cells and possesses intrinsic cell 
adhesive properties [51, 59]. Previous studies utilizing human immune cells which express 
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the cognate receptor for fractalkine, CX3CR1, showed direct cellular binding to endothelial 
cells, which likely aided cellular extravasation [60–62]. Analogous ex vivo studies utilizing 
PCa models demonstrated similar binding kinetics to bone marrow endothelial cells, which 
occurred in a fractalkine-dependent manner [51]. Further investigation determined that, 
though the induction of extracellular matrix-metalloproteases (e.g., ADAM17), AR 
signaling can promote the cleavage of fractalkine from bone cells but not bone marrow 
endothelium [59]. This supports a hypothesis whereby PCa cells bearing CX3CR1, adhere to 
endothelial bone walls expressing fractalkine, and extravasate towards the soluble 
fractalkine gradient generated by the AR signaling axis, ultimately resulting in the 
colonization of the bone microenvironment. Given that first-line therapy for metastatic 
disease involves androgen ablation, it will be interesting to determine how systemic 
hormonal therapy affects both fractalkine cleavage and metastatic growth within the bone. 
Furthermore, as a major mechanism through which PCa tumors evade ADT is through 
production of their own androgens [10, 13, 32], it would be useful to determine if local 
production of androgens within CPRC bone metastatic tumors further promotes fractalkine 
cleavage, bone homing, and subsequent metastatic tumor formation. Future efforts will 
likely define the clinical relevance of this metastatic cascade in both early and late stages of 
disease, and determine if targeting this pathway can be leveraged to limit metastatic tumor 
burden.
3.2 II. AR cofactor deregulation
The discovery of AR-regulated expression of chemokine receptors and ligands represent a 
significant advance in the search for AR-driven pathways, which could potentially be 
leveraged to limit metastatic progression. However, it is improbable that a single AR target 
is responsible for development of metastatic disease. More likely, disease-specific AR-
driven networks are causal for invasive phenotypes and development of metastatic lesions. 
Indeed, recent studies uncovered multiple AR-associated cofactors capable of modulating 
and “reprogramming” genome-wide AR binding events. Such differential AR signatures 
have been associated with enhanced metastatic potential in vitro and in vivo, and have 
putatively significant implications for the development and progression of AR-driven 
metastatic events.
3.2.1 FOXA1 controls AR signaling and metastatic events in PCa—The ability of 
AR to localize to sites of transcriptional regulation upon activation is highly dependent on 
chromatin state and structure. Repressed, or closed, chromatin is often defined by repressive 
histone marks (such as H3K9me2) and lacks enrichment for transcriptional regulators, like 
AR [63–65]. Conversely, active chromatin structures are associated with mono- and 
dimethylation marks on H3K4 (H3K4me1 or H3K4me2), which are often coupled to sites of 
active transcription [63–65]. In the context of hormone-dependent tissues, such markers of 
active transcription are often enriched for binding of the FOXA family of transcription 
factors, also known as “pioneer factors” that facilitate site-specific chromatin remodeling 
and subsequent nuclear receptor binding [63, 64, 66–69]. Importantly, genome-wide 
analysis of the AR cistrome in PCa cells found a high degree of overlap with the FOXA 
family of proteins (nearly 70 % overlap) [68], consistent with the known role of FOXA 
factors serving as pioneer factors, which help to define both active and repressed chromatin 
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states. More specifically, FOXA1 has been demonstrated to be a critical mediator of AR 
signaling in PCa, as loss of FOXA1 in AR-positive PCa cells, decreased both cell growth 
and AR signaling (as determined by AR target gene levels) [70, 71]. Moreover, analysis of 
the AR cistrome in the CRPC line LNCaP-Abl defined a critical role for FOXA1 in 
mediating AR recruitment to critical cell cycle genes (e.g., UBE2C), which facilitated 
castration-resistant growth [55]. Consistent with hormone-dependent AR signaling, loss of 
FOXA1 dramatically decreased growth at this stage indicating that FOXA1 is required for 
AR-driven proliferative events in both early and late stages of disease [55]. Contrary to what 
might be expected, knockdown of FOXA1 did not eliminate AR binding across the genome. 
In fact, depletion of FOXA1 levels resulted in an increase of total AR binding events 
genome wide (13,505 unique binding events with knockdown) [68, 70], indicating that 
tumor-associated elevation of FOXA1 levels dramatically restrict the AR cistrome, which 
likely results in AR-driven signatures responsible for both proliferative and metastatic 
events. Future efforts will aim to better define the functions of FOXA1 responsible for such 
divergent AR functions, and the downstream targets responsible for mediating aggressive 
phenotypes.
Given the knowledge above, it is not surprising that a number of studies have aimed to 
characterize the expression patterns of FOXA1 in lethal metastatic disease. Interestingly, 
however, FOXA1 levels have been reported as both elevated or diminished in PCa [71–74]. 
Such discrepancies could be attributed to potentially novel functions of FOXA1, 
independent of nuclear receptor signaling. Analysis of the FOXA1 cistrome in Abl cells 
demonstrated androgen-independent binding of FOXA1 to cyclin E2 regulatory loci, which 
resulted in increased expression of cyclin E2 and progression through cell cycle [71]. Loss 
of FOXA1 dramatically reduced cellular growth of CRPC cells, while ectopic expression of 
cyclin E2 restored proliferative capacity in this context [71], substantiating AR-independent 
roles of FOXA1 in CRPC-specific proliferation. Conversely, independent studies also 
reported decreased levels of FOXA1 from metastatic tissue, and demonstrated an association 
between FOXA1 loss and enhanced metastatic potential [73]. Chip sequencing analyses of 
the FOXA1 cistrome in LNCaP cells defined a prominent FOXA1 binding site within the 
intragenic region of the SNAI2(Slug) gene, which was associated with low expression of 
Slug and limited migratory potential [73]. FOXA1 depletion dramatically increased Slug 
expression, which enhanced the invasive potential of these cells and promoted a 
dedifferentiation signature [73]. Such data implicate divergent roles of FOXA1 in mediating 
aggressive phenotypes in a prostate-specific context, and suggest that the functions of 
FOXA1 in PCa appear to be complex and highly cell type specific. While elevated levels of 
FOXA1 appear necessary to maintain CRPC-specific growth, depletion of FOXA1 promotes 
lethal metastatic events associated with patient mortality. Furthermore, recent deep 
sequencing of patient samples has uncovered mutations within the coding regions of the 
FOXA1 gene in late stage disease, some of which have the potential to affect FOXA1/DNA 
interactions and/or function [75–77]. Future efforts will focus on elucidating the context-
specific functions of FOXA1, and these newly identified mutants, in promoting aggressive 
tumor phenotypes, and better define the role of AR in such events.
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3.2.2 BAF57 deregulation promotes AR-dependent metastatic events—While 
pioneer factors like FOXA1 have been shown to play critical roles in defining the AR 
cistrome, other classes of DNA-associated co-factors have also demonstrated an ability to 
modulate disease-associated AR binding events. The SWI/SNF complex represents such a 
class, and functions as a multisubunit chromatin remodeling oligomer, which facilitates 
context-dependent gene activation or repression. The complex itself consists of a core 
ATPase (either BRG1 or BRM) and a host of associated cofactors, which help to define 
genome-wide specificity and tissue-specific gene expression programs [78–80]. Alterations 
or changes in the subunits that comprise the complex can dramatically affect the genomic 
localization or targets of SWI/SNF culminating in aberrant transcriptional profiles and 
cellular function [80]. Consequently, deregulation of SWI/SNF subunits is common in many 
tumors, including PCa [79, 81, 82]. Clinical evidence suggests that BAF57, a nonessential 
accessory SWI/SNF subunit is dramatically elevated in metastatic PCa lesions [82]. 
Furthermore, there is substantial evidence to suggest that BAF57 functions as a direct AR 
cofactor, enhancing AR-dependent transcriptional regulation and associated growth [81–83]. 
Microarray profiling of BAF57 upregulation in hormone-dependent cell lines confirmed 
such conclusions, where BAF57 induction was sufficient to promote ligand-independent AR 
activity under conditions mimicking castration (as monitored by the clinically relevant 
targets (KLK3, TMPRSS2, and FKBP5)) [82]. Interestingly, in addition to classical AR 
targets, gene ontology analysis uncovered a subset of BAF57-regulated genes involved in 
migration and invasion, specifically integrin alpha 2 (ITGA2). Genome-wide interrogation of 
the ITGA2 locus uncovered a putative AR binding event in a distal intragenic region, which 
was co-occupied by both BAF57 and AR (in a hormone-independent fashion) [56, 82]. 
Further analysis of SWI/SNF occupancy at this site in the presence of elevated BAF57 
identified enrichment of BRG1, indicating that SWI/SNF activity is likely required for the 
AR/BAF57-mediated induction of ITGA2 under castrate conditions. Consonantly, isogenic 
models of BAF57 deregulation confirmed elevated levels of integrin alpha-2 at the protein 
level, which was associated with enhanced migratory and invasive phenotypes in vitro[82]. 
Blocking integrin alpha-2 function at the cell surface with neutralizing antibodies 
dramatically inhibited the migratory potential of both control and BAF57-expressing cells, 
suggesting that integrin alpha-2 is required for basal and BAF57-induced phenotypes [82]. 
Collectively, these data implicate SWI/SNF perturbations in the pathobiology of AR-driven 
metastatic events in response to hormone therapy, and provide novel targets which could be 
leveraged for therapeutic benefit. It will be vital to define both the BAF57 and AR cistromes 
in models of BAF57 deregulation in order to more completely understand the molecular 
mechanisms that drive BAF57/AR-mediated metastatic phenotypes.
3.2.3 Cyclin D1b alters AR function to promote metastatic events—In addition to 
BAF57 and FOXA1, cell cycle-specific AR cofactors are also likely to play a role in the 
development of metastatic disease. Cyclin D1b is a tumor-specific splice variant of the well-
characterized cell cycle regulator cyclin D1, which arises due to a failure to splice at the 
exon4/intron4 boundary of the pre-mRNA, resulting in the incorporation of intron 4 and the 
introduction of an early stop codon [84]. The resulting protein thus lacks all sequences 
encoded by the terminal exon (exon5) and harbors a unique 33 amino acid C-terminus 
encoded by intron 4 [84]. Numerous studies aiming to define the biological and biochemical 
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consequences of cyclin D1b induction have uncovered novel functions for this splice variant 
in tumor biology, which differ dramatically from full-length cyclin D1 (cyclin D1a). For 
example, expression of cyclin D1b but not cyclin D1a was sufficient to promote tumor 
formation in fibroblasts [85], enhanced the migratory potential of bladder cancer cells [86], 
and was associated with increased resistance to ER antagonists in breast cancer models [87]. 
Investigation in PCa-specific models uncovered a unique role for D-type cyclins in 
modulating AR activity. Consistent with the known role of D-type cyclins as transcriptional 
modulators, previous reports have described cyclin D1a as a potent regulator of AR, capable 
of directly inhibiting AR transactivation and subsequent AR activity (as determined by PSA 
readout) [88–91]. Similar studies assessing the consequences of cyclin D1b expression on 
AR activity determined that while still able to functionally interact with AR, cyclin D1b was 
unable to negatively regulate AR function [92]. Such data are congruent with clinical 
observations aiming to define expression patterns of both cyclin D1a and cyclin D1b in 
primary disease. Only a small number of tumors scored positive for cyclin D1a (7 %), while 
nearly 30 % of all primary tumors demonstrated positive staining for cyclin D1b [93]. 
Further analyses of expression patterns across non-neoplastic and cancerous tissues 
determined that while there was no induction in cyclin D1a levels as a function of 
tumorigenesis, there was a marked increase in cyclin D1b levels in cancerous tissues [93]. 
These data implicate cyclin D1b as a clinically relevant oncogene in PCa, with distinct 
functions from that of cyclin D1a.
Given the established oncogenic functions of cyclin D1b and the induction of this splice 
variant in clinical samples, follow-up studies aimed to define the consequence of cyclin D1b 
on both tumor phenotypes as well as AR activity in PCa. Isogenic models of cyclin D1b 
induction demonstrated that cyclin D1b-expressing cells harbored enhanced invasive 
potential which was critically dependent on an intact AR signaling axis [94]. Subsequent 
microarray analyses defined a large transcriptional regulatory network uniquely regulated by 
cyclin D1b, which was enriched for genes associated with migration and invasion. Among 
the most prominently regulated was the transcriptional regulator SNAI2, a known AR-
regulated gene implicated in metastatic progression PCa [73, 95, 96]. Importantly, induction 
of cyclin D1b resulted in occupancy of both cyclin D1b and AR at SNAI2 regulatory loci, 
which correlated with active marks of transcription (acetylated histone H4) and well as 
enhanced transcriptional output [94]. Notably, depletion of Slug dramatically inhibited all 
cyclin D1b-induced phenotypes, indicating that Slug is a critical downstream mediator of 
cyclin D1b/AR-driven phenotypes in vitro [94]. Parallel studies in vivo determined that 
enhanced Slug expression dramatically increased metastatic growth at distal soft tissues 
(liver and lung) [94], an event that is clinically associated with resistance to 
chemotherapeutics and a poor prognosis [97]. Finally, analysis of CRPC tumors samples 
uncovered a strong positive correlation between cyclin D1b and Slug expression, indicating 
that the cyclin D1b/AR/Slug axis is preserved in human tumors [94]. Taken together, these 
data suggest that cyclin D1b hijacks the AR signaling axis to promote expression of genes 
(SNAI2), responsible for metastatic progression and ultimately patient mortality. Critical 
next steps will aim to better define both the cyclin D1b and AR cistrome to better 
understand the molecular underpinnings of cyclin D1b action on AR-driven metastatic 
events.
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3.3 III. AR-dependent gene fusions and downstream effectors
While there is substantial evidence to suggest that AR cofactors significantly influence AR 
signaling networks to promote metastatic phenotypes, little is known as to how such factors 
are induced or regulated in human disease. While future efforts will characterize these 
pathways to better define the oncogenic cascades responsible for their expression, a class of 
AR-driven genetic fusions has been identified clinically, and are associated with progression 
to metastatic disease. As will be discussed, expression of these fusion products and 
downstream effectors is regulated as a function of AR activity, which can feedback to after 
the AR cistrome, culminating in an AR transcriptome which fosters invasive disease.
3.3.1 AR-regulated TMPRSS2: ETS fusions—Few genetic aberrations have been 
associated with the early stages of PCa, which has hindered the ability to stratify prostate 
cancer into subtypes. However, a chromosomal fusion event, which occurs between the 
regulatory locus of an AR-responsive gene (TMPRSS2) and the coding region of known 
oncogenic factors (erythroblast transformation specific, ETS genes) was identified in human 
prostate cancer samples. While reports vary, it is estimated that nearly half of all primary 
PCas harbor some form of this genetic fusion [98–103], which in some studies was 
associated with early onset of disease and a more aggressive, androgen fueled, phenotype 
[104]. Genetic profiling obtained from primary tumors has identified a multitude of fusion 
events which occur between the ETS family of transcriptional regulators (ERG, ETV1, 
ETV4, ETV5, and FLI1) and the regulatory locus of TMPRSS2, the most common of which 
occurs between the regulatory locus of TMPRSS2 and coding sequence of ERG [102, 103, 
105, 106]. While it is still unclear as to how these fusions arise, there is evidence to 
implicate the AR signaling pathway in their formation [107, 108]. In vitro models suggest 
that upon androgen stimulation, AR facilitates a bridging event between the TMPRSS2 and 
ETS loci, which fosters DNA recombination at low frequency [107, 108]. Importantly, while 
the mechanisms behind the fusions initiation are still under investigation, their clinical 
relevance has been suggested by clinical analyses. In a recent study where treatment 
involved watchful waiting, patients who were positive for the fusion had more aggressive 
disease and showed a worse prognosis as compared to fusion-negative patients [109]. Such 
data indicate that fusions may play a role in the pathogenesis and progression of PCa.
Multiple models of fusion-positive PCa (both in vitro and in vivo) have been generated in 
order to define the oncogenic pathways regulated by ERG, which promote aggressive 
disease. In vitro, the VCaP line (derived from a vertebral metastasis) harbors an endogenous 
fusion between TMPRSS2 and ERG, and is highly responsive to AR activation. While still 
dependent upon AR signaling for growth and survival, modulation of fusion expression did 
not affect growth, tumor formation, or survival, yet drastically affected the invasive capacity 
of these cells [110]. This is congruent with a number of in vivo studies which demonstrate 
that neither induction of ERG or ETV1 alone is not sufficient to promote neoplastic events 
in the prostate [57, 111]. However, in combination with PTEN deficiency (PTEN +/−) 
prostate-specific ERG induction promoted aggressive and invasive adenocarcinoma by 8 
weeks, with some mice developing poorly differentiated tumors by 12 weeks [57]. 
Mechanistically, these aggressive phenotypes were attributed to changes in the AR cistrome, 
which promoted programs of migration and angiogenesis [57]. Furthermore, parallel studies 
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aiming to define the unique AR cistromes between fusion-positive (VCaP) and fusion-
negative (LNCaP) cells confirmed the concept that ERG alters the AR cistrome [112]. While 
there is some discrepancy between the signatures of these studies, both describe ERG-driven 
alterations of the AR cistrome, which are associated with enhanced invasive/metastatic 
potential. The latter also defines an important role for the histone methyltransferase EZH2 in 
ERG-mediated phenotypes [112]. EZH2 is well characterized for its role in maintaining 
stem cells in a dedifferentiated state, and has been shown to be elevated in metastatic/
advanced disease [113, 114]. In PCa models, ERG-induced expression and activity of 
EZH2, which resulted in the repression of well-known EZH2 target genes (e.g., CDH1 and 
DAB2IP) and signatures representative of a dedifferentiated state [115]. Given that EZH2 
has recently been implicated as an AR cofactor requisite for CRPC-specific AR signaling 
[115], it will be critical to determine how ERG, AR, and EZH2 function together to define a 
genome landscape that promotes lethal metastatic disease.
3.3.2 SOX9: effector of ERG function in PCa—SOX9 belongs to the SOX family of 
transcription factors that have well-documented roles in the regulation of developmental 
processes as well as in disease progression [116, 117]. In adult tissues (e.g., liver and 
pancreas), it contributes to the maintenance of stem-like progenitor cells, promoting 
programs of dedifferentiation and self-renewal [118–120]. In the developing prostate, SOX9 
is required for proper ductal morphogenesis, and loss dramatically impairs prostatic 
architecture and function [121]. While both SOX9 and AR are required for proper 
development of the prostate, each is localized to different epithelial compartments in luminal 
tissue [121]. SOX9 expression is typically limited to the AR-negative/low basal cells, 
distinct from the AR-positive, SOX9 low, luminal cells [121]. Interestingly, however, AR 
and SOX9 are coexpressed in a subset of primary PCa [122, 123]. Analysis of a large 
number of primary PCa tumors identified elevated SOX9 expression in patients who 
harbored TMPRSS:ERG fusions, a signature which was further enriched in CRPC 
metastatic tumors [124]. Given the known roles of both ERG fusions and SOX9 in 
promoting metastatic phenotypes, it was likely that these pathways cooperated to enhance 
PCa progression and metastasis. Modeling this event using isogenic lines of fusion-positive 
disease confirmed that androgen-induced ERG expression promoted elevated levels of both 
SOX9 transcript and protein, while knockdown of either ERG or SOX9 was sufficient to 
inhibit invasive properties in vitro [124]. Importantly however, exogenous expression of 
SOX9 was unable to promote invasive phenotypes in the absence of androgen, indicating 
that additional androgen-regulated genes are required for ERG/SOX9-mediated metastatic 
events [124]. Furthermore, elegant mouse models utilizing prostate-specific inducible SOX9 
constructs demonstrated that exogenous SOX9 was sufficient to promote PIN formation and 
localized invasion in hormone-proficient animals [124]. These phenotypes were further 
enhanced in a PTEN heterozygous background, indicating that ERG/SOX9-driven pathways 
cooperate with clinical relevant genetic alterations to promote both PCa progression and 
invasion. Such data demonstrate that SOX9 is a critical mediator of ERG-driven phenotypes 
in PCa.
While ERG expression was sufficient to drive SOX9 expression in vitro and in vivo, the 
underpinning mechanisms behind such induction remained unclear. ChIP-Seq studies 
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analyzing the ERG cistrome in fusion-positive models uncovered an enrichment of ERG 
binding over a 2 kb region proximal to the 3′ UTR of the SOX9 [124]. Interestingly, analysis 
of the AR cistrome found strong localization of AR within this region, which was lost upon 
ERG knockdown. Co-occupancy of both AR and ERG was associated with active marks of 
transcription and enhanced SOX9 expression [124]. Conversely, in fusion-negative models, 
AR activity decreased expression of SOX9 transcript and protein, and was instead only 
recruited to an enhancer-like region upstream of the SOX9 gene, implicated in 
transcriptional repression [124]. These data indicate that ERG can rewire the AR cistrome to 
promote expression of genes associated with cancer progression and metastasis. Given the 
knowledge that SOX9-mediated phenotypes require additional AR targets, it will be critical 
to determine which parallel pathways are governed by AR and SOX9/ERG in order to better 
define networks which can be exploited for patient benefit.
4 Conclusions and key questions
There is an abundance of clinical data to substantiate the AR signaling axis as a critical 
driver of metastatic disease at both the hormone therapy-sensitive and castration-resistant 
states. The findings described herein illuminate multiple pathways governed by AR which 
are responsible for the induction of prometastatic events, and broaden our understanding of 
disease-associated AR signatures (Fig. 2). In most cases, expression of critical AR cofactors 
was responsible for mediating such signatures, in essence rewiring the AR signaling axis to 
promote programs of invasion, migration, survival, and growth. While identification of these 
unique programs represents a significant leap forward in the attempt to thwart progression to 
lethal metastatic disease, there are several gaps in knowledge that have yet to be addressed. 
First, despite the identification of numerous AR cofactors associated with metastatic disease 
(ERG, EZH2, cyclin D1b, BAF57, etc.) PCa still suffers from a lack of biomarkers which are 
effective at predicting metastatic events. While most of the cofactors described above have 
demonstrated the ability to promote prometastatic phenotypes in AR-positive cells, it 
remains unclear if these markers alone are sufficient to predict metastasis or therapeutic 
outcome in the clinical setting. Definition of the co-occurrence of each of these cofactors in 
human disease will be critical to refine clinical signatures which more accurately predict 
progression to metastatic disease. Second, how does expression of multiple AR cofactors 
within a given tumor affect the AR cistrome and downstream biological events? Given, the 
heterogeneity of PCa tumors, it is likely that multiple disease-associated AR cofactors are 
expressed within a given tumor/tumor cell. While current models have examined each of 
these factors in isolation, critical next steps will aim to build off of clinical knowledge to 
better define and model the AR interactome, and identify clinically relevant targets and 
downstream effectors. Third, what regulates the expression of AR cofactors which promote 
progression to lethal disease states? Outside the identification of AR-driven expression of 
genetic fusions, little is known as to how each of these proteins are regulated. While current 
emphasis has been directed toward elucidating the downstream consequences of their tumor-
associated expression, identification of the upstream oncogenic pathways that mediate their 
induction could offer novel avenues for therapeutic intervention to curtail development of 
metastatic lesions. Fourth, are AR-driven metastatic signatures preserved between hormone 
therapy sensitive and CRPC tumors? Genome-wide studies strongly suggest that the AR 
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cistrome changes during the transition to CRPC, yet few models have been established 
which have characterized the function of critical AR cofactors and downstream mediators on 
the AR cistrome in this stage of disease. Uncovering the function of the aforementioned 
factors in CRPC will help define disease state-specific AR signatures involved in metastatic 
events at this stage. Finally, it is time to directly treat the primary tumor in disseminated 
disease? It is uncommon for primary tumors to be resected after the detection of distant 
metastases. Consequently, it remains possible that future distant metastases also originated 
from this same primary site. Are these primary sites of CRPC tumors as indolent as 
expected, or are they in essence factories for disseminated tumor cells? While clinical trials 
directly testing these hypotheses have been proposed, little is known as to the role of 
primary tumors in advancing metastatic CRPC. Ultimately, elucidation of the sites 
responsible for such lethal metastatic events could provide novel avenues for intervention to 
limit the spread of lethal CRPC, dramatically improving patient morbidity and mortality.
In summary, is it clear that the AR pathway is critical for the development and progression 
to metastatic CRPC. Recent advances have uncovered dramatic changes in the AR cistrome 
as a function of disease progression, often attributed to altered expression of critical AR 
cofactors. Such changes have been demonstrated to not only promote the transition to 
CRPC, but also influence PCa-specific metastatic potential. Further investigation into the 
pathways downstream of both AR and these cofactors will likely uncover novel targets that 
can be targeted along side of AR to limit the development of lethal metastatic disease and 
ultimately enhance patient survival.
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Fig. 1. 
Therapeutic options for patients diagnosed with prostate cancer. Therapeutic options for 
localized PCa often involve surgery in combination with some form of radiation therapy. In 
contrast, advanced or metastatic disease leverages the requirement of androgens for tumor 
growth, utilizing systemic therapy to limit androgen production and directly inhibit AR 
activity. Once resistant to first-line hormonal therapy, options to limit tumor growth and 
progression are limited, and consist of second-line hormonal therapy or taxane-based 
chemotherapeutics. While there are several options which are providing benefit in the 
chemotherapy-resistant space, a number of clinical trials are currently ongoing which offer 
promise for earlier intervention to help thwart progression to lethal CRPC [34, 36, 38, 39, 
125–129]. Trials can be found online at www.clinicalrials.gov: trial #NCT01171898, 
NCT01414283, NCT01695044, NCT00694551, NCT00705835, NCT01804465, 
NCT00113984, NCT01420965, NCT01078662, NCT00471432, NCT01548807, and 
NCT01546987. *Clinical trials are currently in the planning stages at the University of 
Michigan and Thomas Jefferson University
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Fig. 2. 
Cofactor-induced AR cistromes that promote metastatic phenotypes. A multitude of disease-
associated AR cofactors have been identified in both primary and metastatic disease, which 
can impinge upon the AR cistrome to promote divergent AR binding events, culminating in 
transcriptional programs responsible for metastatic phenotypes. From left to right; (1) cyclin 
D1b co-occupied SNAI2 regulatory loci (Androgen Receptor Occupied Region 1—AROR1 
and AROR2) with AR, promoting both AR occupancy and chromosomal looping, resulting 
in enhanced Slug expression and metastatic progression (Transcriptional Start Site—TSS) 
[94]; (2) in fusion-positive disease, ERG binding at a 3′ SOX9 enhancer region (site 2–S2) 
facilitates AR recruitment to this site, resulting in enhanced SOX9 expression and increased 
invasion and tumor growth in vivo [124]; (3) tumor-associated elevation of BAF57 levels 
promote AR occupancy within an intronic enhancer of the ITGA2 gene (AROR1) in a 
ligand-independent manner, recruiting necessary SWI/SNF subunits to promote ITGA2 
transcription and facilitate invasive and migratory phenotypes in vitro [82]; (4) Elevated 
levels of FOXA1 localize to sites on chromatin and restrict the total number of AR binding 
events genome wide. AR binding events, in this context, are thus enriched for FOXA1 
binding motifs, and are associated with tumor-specific programs of growth and survival [68]
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